Ohr falls on AMD data

Ohr Pharmaceutical Inc. (NASDAQ:OHRP) fell $3.66 (32%) to $7.74 on Tuesday after interim Phase II data showed its squalamine eye drops ( OHR-002) for wet age-related macular degeneration failed to significantly improve the primary endpoint. Squalamine plus Lucentis ranibizumab as needed did not significantly reduce the mean number of Lucentis injections from baseline to week 38 vs. placebo plus Lucentis as needed (6.2 vs. 6.4 Lucentis injections). Squalamine plus Lucentis as needed also showed non-significant improvements vs. placebo plus Lucentis as needed on secondary endpoints of visual acuity. Ohr said the interim analysis was not designed to include a prespecified analysis of efficacy or futility. ...